Algeria’s Saidal Group, in partnership with Novo Nordisk, has launched a new generation of insulin pens in the Algerian market. The introduction of Tresiba insulin pens marks a significant step in their strategic collaboration, aimed at improving diabetes care and strengthening national health security.
The launch ceremony took place at Novo Nordisk’s headquarters in Boufarik, Blida province. Attendees included Nabila Ben Yagzer, CEO of Saidal Group, Hamza Ben Harkat, General Manager of Novo Nordisk Algeria, as well as senior officials and representatives from national and local authorities.
Both parties emphasized that diabetes poses a major public health challenge in Algeria. This shared concern has driven them to intensify their efforts and work closely to accelerate the implementation of this vital project. Initial discussions began in September, followed by the signing of a memorandum of understanding and a contract in October. This culminated in the product’s availability in the national market today.
A statement indicated that the full production process has commenced at Saidal’s Constantine site, with the goal of localizing the manufacturing of this medication as quickly as possible. The agreement also stipulates the gradual integration of innovative therapeutic solutions developed by Novo Nordisk. This aims to ensure that Algerian patients benefit from modern and effective treatments that meet international standards.
Authorities have stated that this initiative represents a qualitative leap forward in the management of diabetes patients. It aligns with the national strategy to enhance local pharmaceutical production, reduce import dependence, and bolster the country’s health security, in accordance with the directives of President Abdelmadjid Tebboune. This partnership underscores a commitment to providing advanced healthcare solutions for the Algerian population.
